NeuroThera Labs Inc. (TSXV: NTLX), a Toronto-based clinical-stage pharmaceutical company, has highlighted the publication of three U.S. patent applications covering novel combinations of LSD, ketamine and ibogaine with its proprietary palmitoylethanolamide (PEA) technology. The applications, developed through an ongoing collaboration with Clearmind Medicine Inc. (Nasdaq: CMND), target potential therapeutic uses in mental health disorders, pain and substance use disorders. The announcement signals continued growth in NeuroThera's intellectual property position as the company seeks to advance neuropsychiatric treatment options.

Key Points

  • NeuroThera Labs Inc. (TSXV: NTLX) is a clinical-stage pharmaceutical company focused on central nervous system disorders
  • Three U.S. patent applications published covering PEA combinations with LSD, ketamine and ibogaine for potential therapeutic uses
  • Targeted indications include depression, PTSD, pain and substance use disorders; a prior application covering MDMA and N-acylethanolamines was previously announced
  • Investors may be watching for updates on patent grant progress and clinical development milestones under the Clearmind collaboration

Three New U.S. Patent Applications Published Through Clearmind Partnership

As part of NeuroThera's ongoing collaboration with Clearmind Medicine Inc., three U.S. patent applications have been published covering novel combinations of LSD, ketamine and ibogaine with N-acylethanolamines, including PEA. The applications target a range of potential therapeutic indications, including depression, post-traumatic stress disorder, pain and substance use disorders. The release states these filings build on previously disclosed intellectual property from the collaboration, including an earlier U.S. patent application covering combinations of MDMA and N-acylethanolamines for potential treatment of PTSD, anxiety and eating disorders.

PEA Technology at the Core of NeuroThera's Psychedelic Combination Strategy

NeuroThera's proprietary PEA technology serves as the foundation of its intellectual property strategy, with the company seeking to pair it with multiple psychoactive compounds. The disclosure suggests the company views PEA as broadly applicable across neuropsychiatric and substance use disorder indications when combined with psychedelic-derived molecules. The company stated it believes these combinations may support the development of novel therapeutic approaches, though it cautioned that potential therapeutic benefits may not be realised and that patent applications may not ultimately be granted or could be challenged.

Collaboration Focused on Mental Health and Substance Use Treatment Development

NeuroThera and Clearmind have described their joint effort as aimed at bringing safer and more effective treatments to market for mental health conditions they characterise as common and rapidly growing. The companies indicated they remain focused on combining PEA with psychedelic-derived compounds while continuing to build out the supporting intellectual property portfolio. The company did not disclose specific clinical timelines, financing details, or regulatory milestones in the announcement. The immediate share price impact was not clear from available public information.